Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394976> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4308394976 abstract "<h3>Background</h3> Immune checkpoint inhibitors (ICIs) provide enhanced survival benefits for lung cancer patients but can cause potentially fatal adverse events such as checkpoint inhibitor-related pneumonitis (CIP). <h3>Methods</h3> This retrospective, case-control study enrolled 666 lung cancer patients receiving ICIs. Patients exhibiting The CIPs were divided into mild (grades 1–2) and severe (grades ≥3). Logistic regression identified risk factors for all grade and severe CIP, and a risk score for severe CIP was constructed. The model was validated in a separate patient cohort of 187 patients. <h3>Results</h3> In the evaluation cohort, 95 patients developed CIP, of which 37 were severe cases Multivariate analysis revealed age ≥65 years (OR=1.95), current smoking (OR=3.00), chronic obstructive pulmonary disease (COPD, OR=2.49), squamous cell carcinoma (SCC, OR=1.67), prior thoracic radiotherapy (OR=3.12), and extrathoracic radiotherapy during ICI (OR=2.80) were independently associated with CIP events. Five factors, emphysema (OR=2.87), interstitial lung disease (ILD, OR=4.76), pleural effusion (OR=3.00), history of radiotherapy during ICI (OR=4.30), and single agent immunotherapy (OR=2.44) were independently associated with severe CIP and were incorporated into a risk-score model (score ranging 0–17). The area under the model receiver operating characteristic curve for the model was 0.769 in the evaluation cohort and 0.749 in the validation cohort (figure 1). <h3>Conclusions</h3> Advanced age, current smoking, COPD, SCC, previous thoracic radiotherapy and extrathoracic radiotherapy during ICI treatment were independent risk factors for CIP incidence. The risk of severe CIP was observed to be independently associated with emphysema, ILD, pleural effusion, radiotherapy during ICI, and immunotherapy alone. The model has a promising predictive capacity for severe pneumonitis. <h3>Ethics Approval</h3> This study was approved by the local Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (No.2021-38)." @default.
- W4308394976 created "2022-11-11" @default.
- W4308394976 creator A5010520524 @default.
- W4308394976 creator A5033704922 @default.
- W4308394976 creator A5057769470 @default.
- W4308394976 creator A5067865862 @default.
- W4308394976 creator A5082148596 @default.
- W4308394976 date "2022-11-01" @default.
- W4308394976 modified "2023-10-17" @default.
- W4308394976 title "1248 Risk factors and a risk-scoring model for severe checkpoint inhibitor-related pneumonitis in lung cancer patients" @default.
- W4308394976 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1248" @default.
- W4308394976 hasPublicationYear "2022" @default.
- W4308394976 type Work @default.
- W4308394976 citedByCount "0" @default.
- W4308394976 crossrefType "proceedings-article" @default.
- W4308394976 hasAuthorship W4308394976A5010520524 @default.
- W4308394976 hasAuthorship W4308394976A5033704922 @default.
- W4308394976 hasAuthorship W4308394976A5057769470 @default.
- W4308394976 hasAuthorship W4308394976A5067865862 @default.
- W4308394976 hasAuthorship W4308394976A5082148596 @default.
- W4308394976 hasBestOaLocation W43083949761 @default.
- W4308394976 hasConcept C121608353 @default.
- W4308394976 hasConcept C126322002 @default.
- W4308394976 hasConcept C143998085 @default.
- W4308394976 hasConcept C167135981 @default.
- W4308394976 hasConcept C2776256026 @default.
- W4308394976 hasConcept C2776780178 @default.
- W4308394976 hasConcept C2777714996 @default.
- W4308394976 hasConcept C2779524853 @default.
- W4308394976 hasConcept C2779634585 @default.
- W4308394976 hasConcept C509974204 @default.
- W4308394976 hasConcept C58471807 @default.
- W4308394976 hasConcept C71924100 @default.
- W4308394976 hasConcept C72563966 @default.
- W4308394976 hasConceptScore W4308394976C121608353 @default.
- W4308394976 hasConceptScore W4308394976C126322002 @default.
- W4308394976 hasConceptScore W4308394976C143998085 @default.
- W4308394976 hasConceptScore W4308394976C167135981 @default.
- W4308394976 hasConceptScore W4308394976C2776256026 @default.
- W4308394976 hasConceptScore W4308394976C2776780178 @default.
- W4308394976 hasConceptScore W4308394976C2777714996 @default.
- W4308394976 hasConceptScore W4308394976C2779524853 @default.
- W4308394976 hasConceptScore W4308394976C2779634585 @default.
- W4308394976 hasConceptScore W4308394976C509974204 @default.
- W4308394976 hasConceptScore W4308394976C58471807 @default.
- W4308394976 hasConceptScore W4308394976C71924100 @default.
- W4308394976 hasConceptScore W4308394976C72563966 @default.
- W4308394976 hasLocation W43083949761 @default.
- W4308394976 hasOpenAccess W4308394976 @default.
- W4308394976 hasPrimaryLocation W43083949761 @default.
- W4308394976 hasRelatedWork W1971557041 @default.
- W4308394976 hasRelatedWork W2098483241 @default.
- W4308394976 hasRelatedWork W2133367262 @default.
- W4308394976 hasRelatedWork W2333547572 @default.
- W4308394976 hasRelatedWork W2365152911 @default.
- W4308394976 hasRelatedWork W2395953112 @default.
- W4308394976 hasRelatedWork W2407189953 @default.
- W4308394976 hasRelatedWork W2809998966 @default.
- W4308394976 hasRelatedWork W3164268793 @default.
- W4308394976 hasRelatedWork W1912371934 @default.
- W4308394976 isParatext "false" @default.
- W4308394976 isRetracted "false" @default.
- W4308394976 workType "article" @default.